The benefits go away when treatment stops.
A large Danish study of nearly 78,000 adults has revealed that half of those who begin taking semaglutide for weight loss abandon the treatment within a year — a pattern researchers describe as deeply troubling, given that the drug's benefits dissolve the moment it is stopped. The findings, presented in Vienna at a major diabetes conference, expose not merely a question of willpower or side effects, but a structural inequality: the drug costs roughly €2,000 annually, and those with the least means are the most likely to walk away. In this, semaglutide becomes a mirror held up to a broader human dilemma — the distance between what medicine can offer and what society makes accessible.
- Half of 77,310 first-time semaglutide users had quit by the one-year mark, with dropout accelerating sharply — 18% gone by three months, 42% by nine.
- Lead researcher Reimar Thomsen called the trend 'disturbing,' warning that people are treating a long-term medication as a short-term fix, erasing all benefits the moment they stop.
- The burden falls unevenly: young adults aged 18–29 were 48% more likely to quit than middle-aged users, men more likely than women, and low-income patients 14% more likely to discontinue than their wealthier counterparts.
- A €2,000 annual price tag functions less as a medical detail and more as a structural wall — one that determines, often before treatment begins, who gets to stay well.
- Researchers are now pressing for interventions that address not just the drug's pharmacology but the economic and social realities that govern whether patients can realistically sustain it.
When researchers in Denmark set out to track how real people actually use semaglutide — one of the most sought-after weight-loss drugs of recent years — they uncovered something the clinical trials had not fully prepared them for. Among nearly 78,000 adults without diabetes who began the treatment, half had stopped within twelve months. The dropout was not sudden but relentless: nearly one in five quit within three months, nearly half by nine months. Lead author Reimar Thomsen of Aarhus University described it as a disturbing trend rooted in a fundamental misunderstanding. "These medications aren't meant to be a quick fix," he said. "The benefits go away when treatment stops."
The attrition was not shared equally. Younger adults between 18 and 29 were nearly 50% more likely to discontinue than those in their late forties and fifties. Men quit more often than women — possibly because they saw less dramatic results. But the sharpest divide ran along economic lines. People in low-income areas were 14% more likely to abandon treatment, a gap the researchers traced directly to cost: semaglutide carries an annual price of roughly €2,000, a sum that places sustained use out of reach for many households. Those with gastrointestinal histories, psychiatric conditions, or chronic illness were also more likely to stop, whether from side effects or insufficient medical support.
The study, presented at the 2024 European Association for the Study of Diabetes meeting in Vienna, drew on Denmark's unusually precise nationwide health registries. Its authors framed the findings not as a verdict on the drug itself, but as a call to reckon with the conditions surrounding it. With more than half of European adults living with overweight or obesity, the question of who can actually stay on treatment — and who cannot afford to — has become one the medical community can no longer set aside.
Researchers tracking the real-world use of semaglutide have arrived at a sobering finding: half of the people who start taking the drug stop within a year. The medication, a glucagon-like peptide-1 receptor agonist originally developed to manage diabetes, has become one of the most sought-after weight-loss treatments in recent years. But a Danish study of nearly 78,000 first-time users reveals a pattern that troubles the researchers who conducted it—one that suggests many people approach the drug as a temporary intervention rather than a long-term commitment.
The dropout numbers tell a clear story of attrition. Among 77,310 adults without diabetes who began semaglutide treatment, more than 40,000 had quit by the one-year mark. The abandonment accelerated over time: 18 percent stopped within three months, 31 percent by six months, and 42 percent by nine months. By the time a full year had passed, the cumulative effect was stark—half the original cohort had discontinued. Reimar W Thomsen, the study's lead author from Aarhus University in Denmark, called this pattern "a disturbing trend." His concern centers on a fundamental misunderstanding about how these drugs work. "These medications aren't meant to be a quick fix," Thomsen said. "The benefits go away when treatment stops."
But the dropout rates were not evenly distributed across the population. Younger users, those between 18 and 29, were 48 percent more likely to abandon treatment than people aged 45 to 59. Men were 12 percent more likely to quit than women, possibly because they experienced less dramatic weight loss. The most striking disparity, however, emerged along economic lines: people living in low-income areas were 14 percent more likely to discontinue than those in wealthy neighborhoods. The researchers traced this gap directly to cost. Semaglutide runs approximately 2,000 euros per year—a price that functions as an insurmountable barrier for many households, particularly those already struggling financially.
The study also identified other risk factors for early discontinuation. People with a history of gastrointestinal problems, those managing psychiatric conditions, and individuals dealing with chronic illnesses were all more likely to stop the medication. These groups may have experienced side effects that outweighed the weight-loss benefits, or they may have lacked the medical support needed to manage complications. The research was conducted in Denmark, where nationwide health registries allowed scientists to track treatment patterns with precision unavailable in most other countries.
Thomsen and his colleagues presented their findings at the 2024 annual meeting of the European Association for the Study of Diabetes in Vienna, framing the results as a call for better understanding of who can sustain long-term treatment. With more than half of European adults living with overweight or obesity, the question of adherence has become urgent. The gap between those who can afford to stay on semaglutide and those who cannot raises uncomfortable questions about health equity. A drug that works only while you take it becomes, for many, unaffordable the moment you need it most. The researchers suggest that future interventions must account for these realities—not just the pharmacology of the drug itself, but the economic and social conditions that determine whether someone can actually stay the course.
Notable Quotes
These medications aren't meant to be a quick fix. The benefits go away when treatment stops.— Professor Reimar W Thomsen, lead researcher
Understanding who may benefit most from interventions that encourage adherence is essential to improving treatment use.— Professor Reimar W Thomsen
The Hearth Conversation Another angle on the story
Why does it matter that half of people quit? Couldn't some of them just be people who lost the weight they wanted and stopped?
That's a fair question, but the researchers are pointing at something different. These drugs work by suppressing appetite. The moment you stop taking them, that appetite suppression ends. The weight typically comes back. So quitting isn't the same as graduating—it's more like pausing a treatment that requires continuous use.
And the younger people were more likely to quit. Is that because they're less disciplined?
The data doesn't support that reading. The researchers found that cost was the primary driver. Younger people often have less stable income and fewer resources. At 2,000 euros a year, the drug becomes unaffordable for them faster than for older, wealthier users.
So this is really a story about access, not about the drug itself.
Exactly. The drug works. But it only works for people who can afford to keep taking it indefinitely. That's the uncomfortable truth the study is surfacing.
What about the people with gastrointestinal issues who quit? Were they just experiencing side effects?
Likely, yes. But that's also a clue about who this drug is actually suitable for. The study suggests we need better screening and support systems, not just prescriptions.
If the benefits disappear when you stop, what's the long-term vision here? Do people take this forever?
That's the question nobody's answering yet. The researchers are essentially saying: we don't know, and we need to figure it out before we keep promoting this as a solution to obesity.